Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma |
| |
| Affiliation: | 1. McMaster University, Hamilton, Ontario, Canada;2. University of North Carolina, Chapel Hill, NC;3. University of Alberta, Edmonton, Alberta, Canada;4. BC Cancer Agency, Vancouver, British Columbia, Canada;5. Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy;6. Dana-Farber Cancer Institute, Boston, MA;7. University Federico II, Napoli, Italy;8. University of Southern California, CA;9. Massachusetts General Hospital Cancer Center, Boston, MA;10. University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL;1. Division of Trauma, Surgical Critical Care and Acute Care Surgery, Department of Surgery, University of South Alabama, Mobile, AL, USA;2. Department of Surgery, Texas Health Presbyterian, Dallas, TX, USA;3. Division of Trauma, Department of Surgery, Surgical Critical Care and Burns, Loyola University Medical Center, Maywood, IL, USA;1. Bladder Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA;2. Harvard Medical School, Boston, MA, USA;2. National Laboratory for Veterinary Quality Control on Poultry Production, Animal Health Research Institute, PO Box 264-Dokki, Giza-12618, Egypt;1. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;2. Nuclear Medicine and PET Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;3. Clinical Epidemiology and Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;4. Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;5. University of Milan School of Medicine, Milan, Italy;6. University of Alabama (UAB) Comprehensive Cancer Center, Birmingham, AL;1. Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands;2. Department of Surgical Pathology, University Health Network, Toronto, Canada |
| |
| Abstract: | BackgroundOutcomes with concurrent chemoradiotherapy for penile squamous cell carcinoma (PSCC) are unclear, and only anecdotal reports have been published. This study was a retrospective analysis of patients who received concurrent chemotherapy and radiotherapy for PSCC.Patients and MethodsIndividual patient–level data were obtained from 5 institutions for outcomes with concurrent chemoradiotherapy for PSCC. Descriptive statistics were calculated, and univariable Cox proportional hazards regression analysis was conducted to examine the prognostic effect of candidate factors on progression-free survival (PFS) and overall survival (OS).ResultsA total of 26 men were evaluable. The mean age was 60.3 years. The clinical stage was ≤ III in 9 patients (36%) and stage IV in the rest. Soft tissue and visceral metastasis were present in 35% and 20% of patients, respectively. The chemotherapy was cisplatin-based in 92.3% of patients, and the median (range) of external beam radiotherapy administered was 4900 cGy (range, 1800-7000 cGy). The median OS was 6.9 months (95% CI, 5-14), and the median PFS was 5.1 months (95% CI, 2.5-7.0). When excluding patients with M1 disease, the remaining patients (n = 21) had a median OS and PFS of 10.0 months (95% CI, 5-14) and 6.0 months (95% CI, 2.0-7.0), respectively. Baseline neutrophil to lymphocyte ratio (NLR) was significantly associated with survival, and visceral metastasis showed a trend for association with OS.ConclusionsConcurrent chemoradiotherapy demonstrated poor outcomes for locally advanced PSCC. Better understanding of tumor biology and study of novel combinations of biologic agents with radiation are warranted. |
| |
| Keywords: | Chemoradiation Locally advanced Outcomes Penile squamous cell carcinoma Prognosis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
